全文获取类型
收费全文 | 132篇 |
免费 | 10篇 |
国内免费 | 3篇 |
专业分类
妇产科学 | 3篇 |
基础医学 | 23篇 |
口腔科学 | 1篇 |
临床医学 | 9篇 |
内科学 | 98篇 |
特种医学 | 1篇 |
外科学 | 1篇 |
综合类 | 1篇 |
预防医学 | 1篇 |
药学 | 3篇 |
肿瘤学 | 4篇 |
出版年
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 6篇 |
2015年 | 3篇 |
2014年 | 7篇 |
2013年 | 2篇 |
2012年 | 5篇 |
2011年 | 17篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 6篇 |
2007年 | 12篇 |
2006年 | 10篇 |
2005年 | 14篇 |
2004年 | 5篇 |
2003年 | 5篇 |
2002年 | 4篇 |
2001年 | 2篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1996年 | 1篇 |
1994年 | 1篇 |
1992年 | 3篇 |
1989年 | 2篇 |
1980年 | 2篇 |
1968年 | 1篇 |
1966年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有145条查询结果,搜索用时 340 毫秒
1.
Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis 总被引:6,自引:0,他引:6
Takii Y Nakamura M Ito M Yokoyama T Komori A Shimizu-Yoshida Y Nakao R Kusumoto K Nagaoka S Yano K Abiru S Ueki T Matsumoto T Daikoku M Taniguchi K Fujioka H Migita K Yatsuhashi H Nakashima M Harada M Ishibashi H 《Laboratory investigation; a journal of technical methods and pathology》2005,85(7):908-920
2.
Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Clinical and experimental immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Migita K Miyashita T Maeda Y Kimura H Nakamura M Yatsuhashi H Ishibashi H Eguchi K 《Clinical and experimental immunology》2005,142(1):84-91
Type 1 IFN is thought to be implicated in the autoimmune process of SLE. Plasmacytoid dendric cells (DC), which are natural IFN-alpha producing cells, play a pivotal epipathogenic role in SLE. The present study was undertaken to investigate the phenotypic characteristics of peripheral blood DC in SLE patients in comparison with those of healthy controls. Samples from 20 SLE patients and 18 healthy controls were studied. Three-colour flow cytometry was performed to identify myeloid DC, as CD11c(+) lineage marker(-), and HLA-DR(+) cells and plasmacytoid DC, as BDCA-2(+) linage marker(-), and HLA-DR(+) cells. We used the whole blood 'lyse/no-wash' procedure, which allows precise counting of peripheral blood DC. BDCA-2(+) plasmacytoid DC and CD11c(+) myeloid DC were reduced in SLE patients compared with controls. Similarly, BDCA-3(+) DC were reduced in SLE patients. These results indicated that SLE patients had a reduced number of both BDCA-2(+) plasmacytoid DC and CD11c(+) myeloid DC. These alternations of the DC subset may drive the autoimmune response in SLE. 相似文献
3.
Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts 总被引:2,自引:0,他引:2
Migita K Miyashita T Ishibashi H Maeda Y Nakamura M Yatsuhashi H Ida H Kawakami A Aoyagi T Kawabe Y Eguchi K 《Clinical and experimental immunology》2004,137(3):612-616
Leflunomide, an isoxazol derivative structurally unrelated to other immunomodulatory drugs, has proven to be efficacious in the treatment of rheumatoid arthritis (RA). This study was conducted to elucidate the mechanism by which leflunomide mediated antirheumatic effects. We investigated the effects of A77 1726, leflunomide's active metabolite, on mitogen-activated protein kinase (MAPK) activation in IL-1beta-stimulated rheumatoid synovial fibroblasts. The effects of A77 1726 on the secretion of matrix metalloproteinases (MMPs) from rheumatoid synovial fibroblasts were also examined. A77 1726 partially suppressed IL-1beta-induced ERK1/2 and p38 kinase activation. In contrast, A77 1726 efficiently suppressed IL-1beta-stimulated JNK1/2 kinase activation. Although no suppressive effect was demonstrated on MMP-2, A77 1726 markedly inhibited MMP-1, 3, and 13 secretions from IL-1beta-stimulated rheumatoid synovial fibroblasts. Tissue inhibitor of metalloproteinases-1 (TIMP-1) was constitutively produced from rheumatoid synovial fibroblasts and the suppressive effects of A77 1726 on TIMP-1 production were minimal. Our results suggest that the suppression of the MAPK signalling pathway and MMP synthesis in rheumatoid synovial fibroblasts is a possible mechanism for the inhibitory activity of leflunomide against rheumatoid arthritis. 相似文献
4.
Miyaaki H Ichikawa T Yatsuhashi H Taura N Miuma S Usui T Mori S Kamihira S Tanaka Y Mizokami M Nakao K 《Hepatology research》2011,41(12):1216-1222
Aim: The aim of this study was to investigate the relationship among the expression of suppressor of cytokine signaling 3 (SOCS 3) in the liver, the SNPs in the IL28B locus, and the outcome of interferon therapy. Methods: Prior to interferon treatment, we immunostained 67 liver specimens from chronic hepatitis C (CHC) patients who were receiving peginterferon alpha‐2b/ribavirin therapy for suppressor of cytokine signaling 3 (SOCS3), and compared the expression of SOCS3, IL28 polymorphisms and other clinical factors between the patients and compared their eventual outcomes. Results: Significant differences between the low SOCS3 group and high SOCS3 group were found in age, as well as in the platelet, transaminase, gamma‐glutamyl transpeptidase levels. The incidence of high SOCS3 was not significantly different between subjects with the TT genotype and the TG genotype (TT : TG = 71%:29%, P = 0.250). In a multivariate analysis, age (≥65 years old) (odds ratio 0.221 [0.120–0.966], P = 0.045), IL28B gene (genotype TT) (odds ratio 5.422 [1.254–23.617], P = 0.024) and SOCS3 (high) (odds ratio 0.308 [0.104–0.948], P = 0.040) were significant predictors of the interferon response. In patients with the TT genotype, those with low SOCS3 immunostaining showed a high sustained virological response (69%), while the sustained virological rate was low (27%) in the patients with high SOCS3 immunostaining. Conclusions: Using a combination of the SOCS3 immunostained area in the liver and the expression of IL28B single nucleotide polymorphisms might be a useful predictor of hepatitis C virus clearance by interferon therapy. 相似文献
5.
Consumption of wild boar linked to cases of hepatitis E 总被引:9,自引:0,他引:9
Tamada Y Yano K Yatsuhashi H Inoue O Mawatari F Ishibashi H 《Journal of hepatology》2004,40(5):869-870
6.
Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis 总被引:5,自引:0,他引:5
Nakamura M Shimizu-Yoshida Y Takii Y Komori A Yokoyama T Ueki T Daikoku M Yano K Matsumoto T Migita K Yatsuhashi H Ito M Masaki N Adachi H Watanabe Y Nakamura Y Saoshiro T Sodeyama T Koga M Shimoda S Ishibashi H 《Journal of hepatology》2005,42(3):386-392
BACKGROUND/AIMS: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. METHODS: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. RESULTS: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. CONCLUSIONS: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure. 相似文献
7.
Sakamoto Kazumasa Ito Kiyoaki Yotsuyanagi Hiroshi Yatsuhashi Hiroshi Tanaka Yasuhito Hige Shuhei Takikawa Yasuhiro Ueno Yoshiyuki Yamamoto Kazuhide Imazeki Fumio Inoue Jun Kurosaki Masayuki Umemura Takeji Toyoda Hidenori Mita Eiji Michitaka Kojiro Maeshiro Tatsuji Yamada Norie Suetsugu Atsushi Kawanaka Miwa Seko Yuya Matsuura Kentaro Okumura Akinori Fukuzawa Yoshitaka Sugiyama Masaya Mizokami Masashi Yoneda Masashi 《Journal of gastroenterology》2022,57(12):971-980
Journal of Gastroenterology - Hepatitis B virus (HBV) is one of the most prevalent chronic viral infections that causes chronic hepatitis B (CHB). In Japan, genotypes B and C account for most of... 相似文献
8.
Tahata Yuki Hikita Hayato Mochida Satoshi Enomoto Nobuyuki Kawada Norifumi Kurosaki Masayuki Ido Akio Miki Daiki Yoshiji Hitoshi Takikawa Yasuhiro Sakamori Ryotaro Hiasa Yoichi Nakao Kazuhiko Kato Naoya Ueno Yoshiyuki Yatsuhashi Hiroshi Itoh Yoshito Tateishi Ryosuke Suda Goki Takami Taro Nakamoto Yasunari Asahina Yasuhiro Matsuura Kentaro Yamashita Taro Kanto Tatsuya Akuta Norio Terai Shuji Shimizu Masahito Sobue Satoshi Miyaki Tomokatsu Moriuchi Akihiro Yamada Ryoko Kodama Takahiro Tatsumi Tomohide Yamada Tomomi Takehara Tetsuo 《Journal of gastroenterology》2022,57(2):120-132
Journal of Gastroenterology - Direct-acting antiviral (DAA) therapy enables a high rate of sustained virologic response (SVR) in patients with hepatitis C virus associated cirrhosis. However, the... 相似文献
9.
Masao Omata Shuhei Nishiguchi Yoshiyuki Ueno Hitoshi Mochizuki Namiki Izumi Fusao Ikeda Hidenori Toyoda Osamu Yokosuka Kazushige Nirei Takuya Genda Takeji Umemura Tetsuo Takehara Naoya Sakamoto Yoichi Nishigaki Kunio Nakane Nobuo Toda Tatsuya Ide Mikio Yanase Keisuke Hino Bing Gao Kimberly L. Garrison Hadas Dvory‐Sobol Akinobu Ishizaki Masa Omote Diana Brainard Steven Knox William T. Symonds John G. McHutchison Hiroshi Yatsuhashi Masashi Mizokami 《Journal of viral hepatitis》2014,21(11):762-768
Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV – peginterferon and ribavirin for 24 weeks – is poorly tolerated, especially among older patients and those with advanced liver disease. We conducted a phase 3, open‐label study to assess the efficacy and safety of an all‐oral combination of the NS5B polymerase inhibitor sofosbuvir and ribavirin in patients with chronic genotype 2 HCV infection in Japan. We enrolled 90 treatment‐naïve and 63 previously treated patients at 20 sites in Japan. All patients received sofosbuvir 400 mg plus ribavirin (weight‐based dosing) for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after therapy (SVR12). Of the 153 patients enrolled and treated, 60% had HCV genotype 2a, 11% had cirrhosis, and 22% were over the aged 65 or older. Overall, 148 patients (97%) achieved SVR12. Of the 90 treatment‐naïve patients, 88 (98%) achieved SVR12, and of the 63 previously treated patients, 60 (95%) achieved SVR12. The rate of SVR12 was 94% in patients with cirrhosis and in those aged 65 and older. No patients discontinued study treatment due to adverse events. The most common adverse events were nasopharyngitis, anaemia and headache. Twelve weeks of sofosbuvir and ribavirin resulted in high rates of SVR12 in treatment‐naïve and previously treated patients with chronic genotype 2 HCV infection. The treatment was safe and well tolerated by patients, including the elderly and those with cirrhosis. 相似文献
10.
Matsumoto A Tanaka E Suzuki Y Kobayashi M Tanaka Y Shinkai N Hige S Yatsuhashi H Nagaoka S Chayama K Tsuge M Yokosuka O Imazeki F Nishiguchi S Saito M Fujiwara K Torii N Hiramatsu N Karino Y Kumada H 《Hepatology research》2012,42(2):139-149
Aim: The factors associated with hepatitis recurrence after discontinuation of nucleos(t)ide analogs (NAs) in patients with chronic hepatitis B were analyzed to predict the risk of relapse more accurately. Methods: A total of 126 patients who discontinued NA therapy were recruited retrospectively. The clinical conditions of a successful discontinuation were set as alanine aminotransferase (ALT) below 30 IU/L and serum hepatitis B virus (HBV) DNA below 4.0 log copies/mL. Results: Relapse of hepatitis B were judged to occur when maximal serum ALT became higher than 79 IU/L or when maximal serum HBV DNA surpassed 5.7 log copies/mL following NA discontinuation since these values corresponded with mean values of ALT (30 IU/L) and HBV DNA (4.0 log copies/mL), respectively. At least 90% of patients with either detectable hepatitis B e antigen or serum HBV DNA higher than 3.0 log copies/mL at the time of NA discontinuation relapsed within one year. In the remaining patients, higher levels of both hepatitis B surface and core‐related antigens at the time of discontinuation, as well as a shorter course of NA treatment, were significantly associated with relapse by multivariate analysis. Conclusions: It appears that negative results for hepatitis B e antigen and serum HBV DNA lower than 3.0 log copies/mL are essential for successful NA discontinuation, which may be attained by a longer treatment period. Levels of hepatitis B surface and core‐related antigens are also significant factors independently associated with relapse of hepatitis. 相似文献